Big Pharma Defuses Drug Pricing Landmines On Capitol Hill
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
You may also be interested in...
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
House Oversight Committee Chair says AbbVie has failed to comply with requests for documents in committee's investigation of the drug pricing of 12 pharma companies.
Executives from Eli Lilly, Novo Nordisk and Sanofi, as well as representatives from the three largest pharmacy benefit managers, will testify before the House Energy and Commerce Committee’s Subcommittee on Oversight and Investigations April 10; patients, professional organization representatives and academics at an April 2 hearing said they want to know why insulin prices remain out of reach for many diabetics.